BTK
Os inibidores da tirosina quinase de Bruton (BTK) são compostos que especificamente têm como alvo e inibem a BTK, uma enzima crucial envolvida na sinalização do receptor de células B e na regulação da angiogênese. A BTK desempenha um papel significativo na proliferação e sobrevivência de células cancerígenas, particularmente em malignidades hematológicas. Ao inibir a BTK, esses compostos podem interromper a angiogênese e o crescimento tumoral, tornando-os valiosos na terapia do câncer. Na CymitQuimica, oferecemos uma gama de inibidores de BTK de alta qualidade para apoiar sua pesquisa em oncologia, imunologia e angiogênese.
Foram encontrados 146 produtos de "BTK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
GDC-0834 S-enantiomer
CAS:<p>GDC-0834, the S-enantiomer, is a potent and selective inhibitor of Bruton's tyrosine kinase (BTK).</p>Fórmula:C33H36N6O3SPureza:98%Cor e Forma:SolidPeso molecular:596.74CHMFL-EGFR-202
CAS:<p>CHMFL-EGFR-202 is a potent, irreversible inhibitor of EGFR mutant kinase (IC50s: 5.3 nM and 8.3 nM for drug-resistant mutant EGFR T790M and WT EGFR kinases).</p>Fórmula:C25H24ClN7O2Pureza:99.66%Cor e Forma:SolidPeso molecular:489.96(±)-Zanubrutinib
CAS:<p>(±)-Zanubrutinib ((±)-BGB-3111) is a potent and orally available Bruton's tyrosine kinase (Btk) inhibitor that demonstrates superior oral bioavailability,</p>Fórmula:C27H29N5O3Pureza:99.09%Cor e Forma:SolidPeso molecular:471.55NX-2127
CAS:<p>NX-2127 (ETX2514 Triethylamine) is an orally active BTK inhibitor that induces degradation of mutant BTKC481S in cells.NX-2127 has potent antiproliferative</p>Fórmula:C39H45N9O5Pureza:99.07%Cor e Forma:SolidPeso molecular:719.83(R)-Zanubrutinib
CAS:<p>(R)-Zanubrutinib ((R)-BGB-3111) is a selective inhibitor of Bruton tyrosine kinase (BTK).</p>Fórmula:C27H29N5O3Pureza:99.55%Cor e Forma:SolidPeso molecular:471.55Tilfrinib
CAS:<p>Tilfrinib is an effective and selective inhibitor of breast tumor kinase(Brk, IC50 = 3.15 nM) which displays anti-proliferative and anti-tumor activities.</p>Fórmula:C17H13N3OPureza:99.54%Cor e Forma:SolidPeso molecular:275.3(Rac)-PF-06250112
CAS:<p>(Rac)-PF-0625011 is a racemic mix, orally active, selective BTK inhibitor, also targeting BMX and TEC kinases.</p>Fórmula:C22H20F2N6O2Pureza:98%Cor e Forma:SolidPeso molecular:438.43BTK-IN-19
CAS:<p>BTK-IN-19 is a reversible BTK inhibitor with an IC 50 of <0.001 μM .</p>Fórmula:C21H22Cl2N6OCor e Forma:SolidPeso molecular:445.35BTK inhibitor 20
CAS:<p>BTK inhibitor 20 is a potent BTK inhibitor with an IC 50 of 8 nM .</p>Fórmula:C37H42N8O4Cor e Forma:SolidPeso molecular:662.78BTK-IN-18
CAS:<p>BTK-IN-18 is a potent, reversible inhibitor of Bruton's tyrosine kinase (BTK) with an inhibitory concentration (IC50) of 0.002 µM.</p>Fórmula:C20H22Cl2N6OCor e Forma:SolidPeso molecular:433.33BTK-IN-17
<p>BTK-IN-17: selective, oral BTK inhibitor, IC50=13.7 nM, reduces p-BTK Y223/p-PLCγ2 Y1217, anti-inflammatory.</p>Fórmula:C26H23N7O2Cor e Forma:SolidPeso molecular:465.51BTK-IN-11
CAS:<p>BTK-IN-11: potent BTK inhibitor; may research autoimmune, inflammatory diseases, cancer. (Patent WO2022063101A1, Z2)</p>Fórmula:C26H22ClN5O3Cor e Forma:SolidPeso molecular:487.94PF-303
CAS:<p>PF-303, a reversible covalent BTK inhibitor, shows potential for cancer and autoimmune therapy.</p>Fórmula:C22H21ClN6O2Cor e Forma:SolidPeso molecular:436.89BTK inhibitor 13
CAS:<p>BTK inhibitor 13 (compound 8) is an effective and selective BTK inhibitor(IC50: 1.2 nM).</p>Fórmula:C29H26FN5O3Pureza:98%Cor e Forma:SolidPeso molecular:511.55Pirtobrutinib
CAS:<p>Pirtobrutinib: a selective, non-covalent BTK inhibitor effective against BTK C481 mutations, causing tumor regression in lymphoma models.</p>Fórmula:C22H21F4N5O3Pureza:99.76% - 99.94%Cor e Forma:SolidPeso molecular:479.43Cinsebrutinib
CAS:<p>Cinsebrutinib, a Bruton's tyrosine kinase inhibitor, holds potential for research in cancer treatment.</p>Fórmula:C22H26FN3O2Pureza:98%Cor e Forma:SolidPeso molecular:383.46Edralbrutinib
CAS:<p>Edralbrutinib (TG-1701) is a potent BTK inhibitor with anticancer activity and is used in the treatment of tumors, immune system disorders, and blood and</p>Fórmula:C26H21F2N5O3Pureza:99.41%Cor e Forma:SolidPeso molecular:489.47BMX-IN-1
CAS:<p>BMX-IN-1 (BMX kinase inhibitor) is a selective inhibitor of bone marrow tyrosine kinase on chromosome X (BMX, IC50 = 8 nM) and the related Bruton’s tyrosine</p>Fórmula:C29H24N4O4SPureza:98.38%Cor e Forma:SolidPeso molecular:524.59PF-06250112
CAS:<p>PF-06250112 is an effective and highly selective BTK inhibitor (IC50: 0.5 nM.</p>Fórmula:C22H20F2N6O2Pureza:98%Cor e Forma:SolidPeso molecular:438.43TAK-020
CAS:<p>TAK-020 is a potent covalent inhibitor of Btk with potential antitumor activity for the study of rheumatoid arthritis and immune-related diseases.</p>Fórmula:C18H17N5O3Pureza:98.79%Cor e Forma:SolidPeso molecular:351.36BTK inhibitor 1
CAS:<p>BTK inhibitor 1 (Compound 27) is a BTK inhibitor (IC50: 0.11 nM) with an inhibitory effect on B-cell activation in hWB with an IC50 of 2 nM.</p>Fórmula:C24H23FN8O2Pureza:98.24% - 98.91%Cor e Forma:SolidPeso molecular:474.49BMS-935177
CAS:<p>BMS-935177 is a reversible BTK inhibitor with IC50 value of 3 nM.</p>Fórmula:C31H26N4O3Pureza:99.89%Cor e Forma:SolidPeso molecular:502.56BTK inhibitor 18
<p>BTK inhibitor 18 is a selective, potent, covalent, orally active Btk inhibitor (IC50: 142 nM) that exhibits anti-inflammatory effects.</p>Fórmula:C29H25N5O4S2Cor e Forma:SolidPeso molecular:571.67HDHD4-IN-1
CAS:<p>HDHD4-IN-1 (compound 3) is an inhibitor of N-acetylneuraminate-9-phosphate phosphatase (HDHD4) with an IC50 value of 11 μM. It is utilized in the research of neurological disorders.</p>Fórmula:C12H22NO11PCor e Forma:SolidPeso molecular:387.28BMS-986143
CAS:<p>BMS-986143: oral BTK inhibitor, IC50=0.26 nM, potential for autoimmune research, also targets TEC, BLK, BMX, TXK, YES1, ITK.</p>Fórmula:C31H24Cl2N4O4Cor e Forma:SolidPeso molecular:587.45JAK3/BTK-IN-4
CAS:<p>JAK3/BTK-IN-4, a dual inhibitor for JAK3/BTK, shows synergy in autoimmune disease treatment. (Patent WO2021147953A1, compound 003)</p>Fórmula:C21H25ClN8OCor e Forma:SolidPeso molecular:440.93GNE-431
CAS:<p>GNE-431: potent, selective noncovalent Btk inhibitor, IC50=3.2 nM; effective against C481R, T474I, T474M mutants, may counter ibrutinib resistance.</p>Fórmula:C30H32N10O2Cor e Forma:SolidPeso molecular:564.64BIIB129
CAS:<p>BIIB129 is a selective and brain-penetrant BTK covalent inhibitor used to study B-cell proliferation-related diseases.</p>Fórmula:C19H22N6O2Pureza:98.56%Cor e Forma:SolidPeso molecular:366.42RET-IN-14
CAS:<p>RET-IN-14 inhibits RET (IC50: <0.51-9.3 nM) & BTK (C481S) (IC50: 9.2-15 nM), promising for tumor research.</p>Fórmula:C24H23FN8O4Cor e Forma:SolidPeso molecular:506.49BTK-IN-15
<p>BTK-IN-15: Oral BTK inhibitor, IC50 0.7 nM, induces cancer cell apoptosis, selective with anti-tumor effects.</p>Fórmula:C28H24FN5O2Cor e Forma:SolidPeso molecular:481.52WS-11
CAS:<p>WS-11 is a non-covalent reversible inhibitor of BTK, with IC50 values of 3.9 nM for the wild-type and 2.2 nM for the C481S mutant BTK. In addition to strong hydrogen bonding, WS-11 also forms robust π-π interactions with PHE540, and p-π interactions with LYS430 within the active pocket.</p>Fórmula:C26H22FN9O2Cor e Forma:SolidPeso molecular:511.51BTK-IN-16
CAS:<p>BTK-IN-16 is a potential inhibitor of wild-type BTK and C481S mutants.BTK-IN-16 can be used to study various autoimmune diseases and cancers caused by BTK.</p>Fórmula:C15H14N4O2Pureza:99.04%Cor e Forma:SoildPeso molecular:282.3G-744
CAS:<p>G-744 is a selective and orally active inhibitor of Btk (IC50: 2 nM).</p>Fórmula:C29H29N5O3SPureza:98%Cor e Forma:SolidPeso molecular:527.64JAK3/BTK-IN-3
CAS:<p>JAK3/BTK-IN-3: strong dual JAK3/BTK suppressor, promising for autoimmune disease research.</p>Fórmula:C22H28N8OCor e Forma:SolidPeso molecular:420.51BTK-IN-10
CAS:<p>BTK-IN-10 is a potent inhibitor of BTK, acting on wild-type BTK (IC50<5 nM) or mutant BTK (C481S) (IC50<5 nM).</p>Fórmula:C25H24F2N4O2Cor e Forma:SolidPeso molecular:450.48BTK-IN-34
CAS:BTK-IN-34 (compound 9h) functions as a selective BTK inhibitor, exhibiting antiproliferative effects in RAMOS cells by specifically targeting pBTK (Tyr223) while sparing upstream proteins such as Lyn and Syk in the BCR signaling pathway [1].Fórmula:C22H29N3O4SPeso molecular:431.55BTK-IN-38
CAS:<p>BTK-IN-38 (Example 125) is an efficacious inhibitor of BTK. It effectively suppresses the proliferation of DOHH2 and BT474 cells, with IC50 values of 114 nM and 340 nM, respectively.</p>Fórmula:C27H26F2N4O2Cor e Forma:SolidPeso molecular:476.52JAK3/BTK-IN-7
CAS:<p>JAK3/BTK-IN-7 (XL-12), characterized as a JAK3/BTK inhibitor, exhibits IC 50 values of 2 nM and 14 nM for JAK3 and BTK respectively. This compound demonstrates anti-inflammatory properties and is applicable in research related to rheumatoid arthritis [1].</p>Fórmula:C29H30N8O4Cor e Forma:SolidPeso molecular:554.6Brefeldin A 4-O-nicotinate
CAS:<p>Brefeldin A 4-O-nicotinate (CHNQD-01228) is a dual inhibitor of Arf1 and BMX proteins with an IC50 value of 0.22 μM for T24 cell proliferation. It also suppresses T24 cell migration and colony formation in a dose-dependent manner, induces G1 phase arrest, and triggers apoptosis. By targeting BMX proteins, it inhibits the AKT/p-AKT and STAT3/p-STAT3 signaling pathways, while also inhibiting Arf1 proteins to eliminate bladder cancer stem cells and activate antitumor immunity, thus exhibiting anticancer activity. Brefeldin A 4-O-nicotinate is applicable in research related to bladder cancer.</p>Fórmula:C22H27NO5Cor e Forma:SolidPeso molecular:385.453BTK-IN-8
<p>BTK-IN-8: potent, selective covalent BTK inhibitor; IC50=0.22 nM, Kd=0.91 nM; effective in blood CD69 cells (IC50=0.029 μM).</p>Fórmula:C26H36N6O3Cor e Forma:SolidPeso molecular:480.6BTK-IN-6
<p>BTK-IN-6, a potent BTK inhibitor, may treat immune, cardiac, cancer, viral, inflammatory, metabolic, and neurological disorders.</p>Fórmula:C23H22FN5O3Cor e Forma:SolidPeso molecular:435.45Ibrutinib Racemate
CAS:<p>Ibrutinib is a selective, irreversible Btk inhibitor (IC50: 0.5 nM). Ibrutinib Racemate is the racemate of Ibrutinib.</p>Fórmula:C25H24N6O2Pureza:98%Cor e Forma:SolidPeso molecular:440.5Dihydrodiol-Ibrutinib
CAS:<p>PCI 45227 is an active metabolite of the Bruton's tyrosine kinase inhibitor ibrutinib .1PCI 45227 is formed from ibrutinib by the cytochrome P450 (CYP) isoform CYP3A.<br>1.Veeraraghavan, S., Viswanadha, S., Thappali, S., et al.Simultaneous quantification of lenalidomide, ibrutinib and its active metabolite PCI-45227 in rat plasma by LC-MS/MS: Application to a pharmacokinetic studyJ. Pharm. Biomed. Anal.107151-158(2015)</p>Fórmula:C25H26N6O4Cor e Forma:SolidPeso molecular:474.521BTK-IN-25
CAS:<p>BTK-IN-25 (compound 71) is a potent BTK inhibitor, demonstrating an IC50 of 0.77 nM against BTK(C481S) and achieving an IC50 of 1 nM in DOHH2 cells [1].</p>Fórmula:C28H27F2N3O5Pureza:98%Cor e Forma:SolidPeso molecular:523.53JDB175
CAS:<p>JDB175, a selective BTK inhibitor with oral bioavailability, demonstrates excellent penetration through the blood-brain barrier.</p>Fórmula:C26H21F3N4O2Pureza:98%Cor e Forma:SolidPeso molecular:478.47BTK-IN-27
CAS:<p>BTK-IN-27 (example 8), a potent BTK inhibitor with an IC50 of 0.2 nM, demonstrates anti-proliferative effects in TMD8 cells with an IC50 of less than 5 nM.</p>Fórmula:C31H35N7O2Pureza:98%Cor e Forma:SolidPeso molecular:537.66
